AarogyaAI Innovations Pvt. Ltd. diagnoses drug-resistant TB (DR-TB) using artificial intelligence in a few hours so that the patient can be prescribed effective drug treatments for treatment without delay while also ensuring that it remains an affordable and available to people from remote places. See more

Basic Information

Delhi based AarogyaAI Innovations Pvt. Ltd. diagnoses drug-resistant TB (DR-TB) using artificial intelligence in a few hours. The company enables quick and accurate diagnosis of DR-TB so that the patient can be rightly prescribed effective drug combinations for treatment without delay. The test can also precisely mention the drugs and conclude if they would work on the patient. The aim is to make this test available at the most remote place at affordable prices. They have already procured the data and built partnerships with Genotypic and CCAMP in Bengaluru, Lifeline Laboratories, Indian Spinal injuries Centre and Sir Gangaram Hospital in Delhi; and Foundation of Medical Research, IQVIA in Mumbai. Aarogya.AI will also be developing tests for other anti-microbial diseases such as urinary tract infection and cholera in the next phase of growth for the company. See more

Legal Name

:

AarogyaAI Innovations Private Limited

Headquarters

:

Bangalore, Karnataka, India

Business Model

:

B2B2C 

Founding Date

:

May 2019

No. of Employees

:

<10

Core Team

:
1.

Praapti Jayaswal

Co Founder and CEO

2.

Avlokita Tiwari

Co Founder and CTO

Tech30 Pitch
Video not supported in your device
Timeline
2019
true
Apr | Accelerator / Incubator Program
Pitched to the investment committee of Entrepreneur First- a UK-based incubator.
May | Company Incorporation
AarogyaAI Innovations Private Limited was incorporated.
Jun | Advisor Onboarded
Dr. Soumya Swaminathan, Chief Scientist at World Health Organisation, and a tuberculosis physician, was onboarded as an advisor.
Oct | Awards
Best pitch at Shakti Challenge for Women 2019

See More

Target Market

B2B

AarogyaAI is targeting diagnostic labs and hospitals, to offer our services to its patients. B2B2C model.

Client Segment

:

HealthTech / MedTech / Healthcare

Target Companies

:

Startup

Target Geography

:

India

Funding

Total Funding

$250.0k

Investors

:

1.

Entrepreneur First

Detail Round Breakdown

Round 1

$55k

Series Name

:

SEED

Date

:

16th Dec 2020